Document is current
Any future updates will be listed below
-
Authors
Wang, Xiaoshuang
Wu, Zhongen
Zhou, Yan
Yang, Dehua
Zhou, Qingtong
Zhu, Di
Wang, Ming-Wei
Wang, Lu
-
Funding
Funding for this research was provided by:
Science and Technology Commission of Shanghai Municipality (18ZR1403900)
National Natural Science Foundation of China (81872895, 82073881, 81872915, 82073904 and 82011530150)
Innovative Drug and Evaluation Innovation Team for Tumor Immunotherapy of Jinan Science and Technology Bureau (2020GXRC041)
Fudan-SIMM Joint Research Fund (FU-SIMM20181010)
Shanghai Municipal Education Commission (DGF817029-04)
- License Information
-
More Information
Article History
Received: 9 January 2025
Accepted: 6 June 2025
First Online: 1 July 2025
Declarations
:
: The authors declare no competing interests.
: The study protocols were approved by the Ethics Committee of Fudan University Shanghai Cancer Center (050432-4-1911D). All participants were properly familiarized with our study and provided signed informed consent. And the research was carried out in accordance with the Declaration of Helsinki.
